News

• Group adjusted constant-currency (cc) revenues rise by 6%, while adjusted cc EBITDA improves by 5% to record level in first half of 2025
  
  
• Revenues growth in all three business segments – Consumer Healthcare, Generics and Specialty
  
  
• STADA CEO Peter Goldschmidt: ”Despite volatile market conditions, STADA achieved broad-based growth in the first half of this year, based on our diversified portfolio, strong launches and very high employee engagement rates. We were also able to expand our development portfolio with 50 new Business Development & Licensing deals signed in H1 to sustain strong future growth.”

Bad Vilbel, Germany – 28 August 2025 - STADA, a leading healthcare and pharmaceuticals company specializing in Consumer Healthcare, Generics and Specialty pharmaceuticals, achieved strong revenues and earnings growth in the financial first half ended 30 June 2025.

Group adjusted constant-currency (cc) revenues advanced by 6% against H1 2024 to €2.123 billion, entirely on an organic basis. This positive development was also driven by a double-digit increase in revenues by the Group’s Specialty segment.

Adjusted cc earnings before interest, tax, depreciation and amortization (EBITDA) improved by 5% to €481 million, a record level, aided by an adjusted gross margin improvement of 0.7 percentage points against H1 2024 to 49.9%, in part through a strong performance by the Group’s TechOps supply-chain function.

”Despite volatile market conditions,” commented STADA’s CEO, Peter Goldschmidt, “STADA achieved broad-based growth in the first half of this year, based on our diversified portfolio, strong launches and very high employee engagement rates. We were also able to expand our development portfolio with 50 new Business Development & Licensing deals signed in H1 to sustain strong future growth.”

Specialty grows by 18% on ustekinumab launch

An 18% increase against H1 2024 in first-half 2025 Specialty adjusted cc revenues to €486 million was largely attributable to a strong performance and penetration of the Uzpruvo (ustekinumab) biosimilar to Stelara launched from July 2024. This was reinforced by continued broad-based growth of in-market biosimilars such as adalimumab and the introduction of the specialty oncology generics nilotinib and paclitaxel albumin in several European countries. Moreover, the Specialty segment benefitted from increased patient uptake of innovative brands such as Kinpeygo (modified-release budesonide) in nephrology and Lecigon (carbidopa/levodopa/entacapone) in neurology, leveraging STADA’s strong marketing and sales capabilities. 

Consumer Healthcare revenues advanced by 2% against H1 2024 to €779 million, overcoming a decline in Q1 2025 related to a weak cough & cold season. Beyond cough & cold, revenues from the remaining Consumer Healthcare portfolio grew in the mid-single-digit range, driven by the strong performance of key brands such as Nizoral and Zoflora.

Generics adjusted cc revenues moved ahead by 2% against H1 2024 despite exceptionally high revenues in Germany during the first half of 2024 based on favorable one-time effects. Outside of Germany, Generics revenues in other countries increased in the mid-single-digit range during the 2025 first half, driven in part by the launch of the anticoagulant rivaroxaban in several countries. 

As evidence of STADA’s strong growth culture, CEO Peter Goldschmidt pointed to the group’s most recent employee survey, in which 83% of participating employees said they are proud to work for STADA, and 84% believe STADA cares for its employees in line with its purpose of Caring for People’s Health as a Trusted Partner. During the second quarter of 2025, STADA published its latest Group Sustainability Report detailing the environmental, social and governance (ESG) initiatives that have seen STADA rated among the top 3% in the sub-industry pharmaceuticals by Sustainalytics, and among the top 4% of all companies assessed by EcoVadis. In line with the Group’s purpose of Caring for People’s Health as a Trusted Partner, the company also at the end of the second quarter provided comprehensive health-related information and insights through the findings of the STADA Health Report, surveying 27,000 adults across 22 European countries.

“With preparations underway to secure approval for, and launch, Specialty biosimilars including aflibercept, denosumab golimumab and tocilizumab, plus 50 business-development and licensing deals signed during the first half, we have a robust pipeline to support future growth,” asserted Goldschmidt. “Our pipeline is well stocked with blockbuster molecules such as enzalutamide, ivacaftor, ibrutinib, ruxolitinib and palbociclib, as well as several GLP-1 receptor agonists,” he pointed out, “while we continue to strengthen our Consumer Healthcare segment by acquiring strong local brands such as the Fortacell supplements range in the Balkans region.”

“Our exposure to the US market, and to tariff reforms, is very limited, so I am very confident that we have laid the foundations to deliver on our full-year 2025 guidance and beyond,” Goldschmidt concluded.

Disclaimer
Neither this communication nor the publication in which it is contained is for publication or distribution, directly or indirectly, in whole or in part, in or into the United States of America, including its territories and possessions, any state of the United States and the District of Columbia (the “United States”). This communication is not and does not constitute an offer to sell, or the solicitation of an offer to buy or subscribe for, securities to any person in the United States, Australia, Canada or Japan, or any other jurisdiction in which such offer may be restricted or unlawful.
Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state or other jurisdiction of the United States, and may not be offered, sold, subscribed, used, pledged, resold, allotted, delivered or otherwise transferred, directly or indirectly, in or into the United States absent such registration, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements under the Securities Act, and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. There is no intention to register any securities referred to herein in the United States or to make a public offer of the securities in the United States.

About STADA Arzneimittel AG
STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA Arzneimittel AG sells its products in over 100 countries. In financial year 2024, STADA achieved group revenues of € 4,059 million and adjusted constant-currency earnings before interest, taxes, depreciation and amortization (adj. cc EBITDA) of € 886 million. As of 31 December 2024, STADA employed 11,649 people worldwide.

Additional information for journalists
STADA Arzneimittel AG - Media Relations
Stadastrasse 2-18, 61118 Bad Vilbel - Germany
Phone: +49 (0) 6101 603-165
E-Mail: [email protected]
Follow @STADAGroup on LinkedIn

Additional information for capital market participants
STADA Arzneimittel AG - Investor & Creditor Relations
Stadastrasse 2-18, 61118 Bad Vilbel – Germany
Phone: +49 (0) 6101 603-4689
Fax: +49 (0) 6101 603-215
E-mail: [email protected]

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES.